Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Feb 16, 2012 4:02pm
219 Views
Post# 19545363

RE: Article of Interest - Excellent Read

RE: Article of Interest - Excellent Read

[S] Terry

Excellent article, I mentioned the production cost per Au OZ differential (junior to tier one) before. When it is all said and done juniors are a RISKY proposition, BRD included.

BRD appears to be "in distribution", where some players have walked the PPD down in order to cross over a millions shares.

Usually this is a good sign, as it is NORMALLY a precursor to a "free for all" (to the upside). Of course the HFT are also in on the action.

Not a stock for the unschooled (nubie). There is a lot going on here that is not giving recent drilling or production enhancements any credit.

BWDIK?

Pure, ATSs take 31.8%, Alpha warms up its exchange

2012-02-15 17:01 ET - Street Wire

by Stockwatch Business Reporter

<snip>

"Last week Fox News reported that on a normal day four billion shares change hands on the New York Stock Exchange. Recently, one in 10 of those shares, it said, belongs to Bank of America, the high frequency trading stock of the moment. High frequency traders like stocks priced in the single-digits and with lots of shares outstanding; Bank of America closed at $7.98 Tuesday and has 10.5 billion shares outstanding. The stock of the moment in 2009 and 2010 was Citigroup Inc. However, its average daily volume dropped to 50 million from 500 million in May, 2011, after the company rolled back its 29 billion shares 1:10 to 2.9 billion."

 

 

Bullboard Posts